Bile Duct Ligation Liver Fibrosis Model

Bile Duct Ligation Liver Fibrosis Model for Preclinical Efficacy Studies

Bile duct ligation (BDL) is a well-established surgical model of cholestatic liver injury and fibrosis. Ligation of the common bile duct produces bile accumulation, hepatobiliary injury, inflammation, portal pressure changes, ductular reaction, and progressive extracellular matrix deposition.

This model is commonly used to evaluate therapeutic candidates targeting cholestasis-associated liver injury, fibrogenesis, inflammation, biliary remodeling, and fibrosis progression.

At IPST, the BDL model can be used to support preclinical efficacy studies for anti-fibrotic, anti-inflammatory, hepatoprotective, and cholestasis-targeted therapeutic strategies. Functional, biochemical, histological, and morphometric endpoints can be integrated to provide a translational assessment of treatment effect.

Bile Duct Ligation - Methodology

Species: rats
Induction: surgical ligation of the common bile duct
Disease biology: cholestatic liver injury, biliary obstruction, inflammation, ductular reaction, portal pressure changes, and progressive fibrosis
Typical in-life phase: approximately 3 weeks
Typical total study duration: approximately 6 weeks, depending on treatment timing and endpoint requirements
Treatment design: preventive, early intervention, or therapeutic protocols can be implemented according to the sponsor’s mechanism of action
Applications: efficacy testing, fibrosis progression studies, cholestasis-related injury assessment, mechanism-of-action support, and biomarker evaluation

The BDL model produces a robust cholestatic injury phenotype characterized by increased bilirubin, liver enlargement, hepatobiliary injury, and progressive collagen deposition.

Because the model is surgically induced and develops over a defined time course, it is useful for evaluating compounds intended to reduce cholestatic injury, limit inflammatory and fibrotic responses, improve liver pathology, or modulate portal pressure-related outcomes.

Bile Duct Ligation - Readouts & Application

Readouts:

Blood chemistry: ALT, AST, bilirubin, alkaline phosphatase, and additional liver injury markers as required
Cholestasis-related endpoints: plasma bilirubin, liver index, bile duct obstruction-associated injury, and hepatobiliary pathology
Portal pressure: portal venous pressure assessment when relevant to the study design
Histology: H&E and Picrosirius Red staining
Fibrosis assessment: Ishak scoring or study-specific semi-quantitative fibrosis scoring
Collagen quantification: collagen area, fibrosis burden, and morphometric analysis
Inflammation and tissue injury: inflammatory infiltrates, hepatocellular degeneration, necrosis, ductular reaction, and architectural disruption
Biomarkers: tissue or circulating biomarkers can be incorporated to support mechanism-of-action or target-engagement analysis

Application:

The bile duct ligation model is a useful preclinical platform for evaluating therapeutic candidates designed to prevent or treat cholestatic liver injury and fibrosis. The model is particularly relevant when treatment effects must be assessed using both biochemical markers of liver injury and histological evidence of fibrosis, inflammation, and tissue remodeling.

At IPST, the BDL model can support efficacy studies for anti-fibrotic, anti-inflammatory, hepatoprotective, biliary disease, and cholestasis-focused drug-development programs. Endpoint packages can be tailored to the sponsor’s therapeutic hypothesis, including liver injury markers, bilirubin, portal venous pressure, histology, fibrosis scoring, collagen quantification, and biomarker analysis.